RxDoctor Payments Data

William Schwartz, DO

Family Medicine · Jacksonville, FLNPI 1659479764

Payments from drug & device makers

$23,478in general payments, 2019–2025

Across 1,038 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • AbbVie$3K
  • Novo Nordisk$2K
  • Johnson & Johnson$2K
  • Amarin Pharma, Inc.$1K
  • Lilly USA, LLC$1K
  • plus $10K from 45 others

What the payments were for

  • Food & beverage$23,383100%
  • Education$950%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,478 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$144,639
Medicare patients
305
Services billed
2,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$122,833
VraylarCariprazine Hcl60$95,678
MounjaroTirzepatide33$40,568
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$34,084
JardianceEmpagliflozin20$27,902
EliquisApixaban15$23,204
FarxigaDapagliflozin Propanediol18$21,944
VascepaIcosapent Ethyl20$21,861
XareltoRivaroxaban21$17,131
LinzessLinaclotide14$15,098
SymbicortBudesonide/Formoterol Fumarate14$5,124
Aripiprazole36$4,416
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine66$2,316
Atorvastatin Calcium208$1,920
Omeprazole116$1,869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,375$122,83396 claims
AbbVieVraylar, Linzess, Synthroid$2,735$111,60788 claims
Lilly USA, LLCMounjaro$1,195$40,56833 claims
GSKTrelegy Ellipta$1,157$34,08431 claims
Boehringer IngelheimJardiance$164$27,90220 claims
AstraZenecaFarxiga, Symbicort$3,629$27,06832 claims
PfizerEliquis$707$23,20415 claims
Johnson & JohnsonXarelto$1,822$17,13121 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$1,308139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →